Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Pharmaceutical Intelligence

Intelligence for people who need to know what changed before everyone else.

Weekly pharmaceutical intelligence powered by the Humanexa engine.

Explore Humanexa Platform →

Live Intelligence Feed
01/50
RegulatoryMonitorregulatory

FDA Accepts NDA for Vepdegestrant by Arvinas Operations

The FDA has accepted the New Drug Application (NDA) for Vepdegestrant (NDA219835) submitted by Arvinas Operations.

Vepdegestrant · Oncology / Estrogen Receptor Modulator

Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Asset

Vepdegestrant

Indication

Oncology / Estrogen Receptor Modulator

Status

Approved

Signal Score

8.0

Latest

Latest Signals

Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Asset

Vepdegestrant

Indication

Oncology / Estrogen Receptor Modulator

Status

Approved

Signal Score

8.4

Regulatoryhigh signal

FDA Accepts NDA for Vepdegestrant by Arvinas Operations

The FDA has accepted the New Drug Application (NDA) for Vepdegestrant (NDA219835) submitted by Arvinas Operations.

August 2, 2026Read signal →
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Lupin

Asset

FDA

Indication

Metabolic Disorders / Urea Cycle Disorders

Status

Approved

Signal Score

8.4

Regulatoryhigh signal

FDA Approves Glycerol Phenylbutyrate Application by Lupin

The FDA has approved the application ANDA207694 for Glycerol Phenylbutyrate submitted by Lupin.

August 2, 2026Read signal →
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Asset

Unichem

Indication

Neurology / Pain Management

Status

Approved

Signal Score

8.4

Regulatoryhigh signal

FDA Approves Pregabalin Application ANDA219593 by Unichem

The FDA has approved the ANDA219593 application for Pregabalin submitted by Unichem.

August 2, 2026Read signal →

Featured

Featured Intelligence

Deep strategic analysis on the developments most likely to shift portfolio, competitive, and investment decisions.

Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Roche

Asset

Trial Update

Indication

Oncology · KRAS G12C NSCLC

Status

Under Review

Signal Score

9.6

Strategycritical signal

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial

Monitor upcoming data presentations and regulatory submissions related to divarasib, as well as market responses from competitors.

July 2, 2026Read signal →
Score9.6

Signal

Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma

Company

Roche

Category

Strategy

Therapeutic Area

Oncology · Immune-Mobilizing T-cell Receptors

Action

Escalate

Strategycritical signal

Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma

Monitor ongoing research into tebentafusp's application in cutaneous melanoma and the development of other ImmTACs like brenetefusp.

June 17, 2026Read signal →

Coverage

Signal Categories

Regulatory

FDA approvals, label changes, advisory committee outcomes, and global regulatory shifts that reshape asset and portfolio strategy.

Browse signals →

Clinical

Phase readouts, trial design shifts, endpoint changes, and safety signals that move the clinical risk-reward calculus.

Browse signals →

Competitive

Pipeline moves, positioning shifts, and competitive dynamics that change how assets are valued and prioritized.

Browse signals →

Market

Pricing, access, demand, and commercialization trends that influence revenue outlooks and investment theses.

Browse signals →

M&A Watch

Deal activity, strategic fit signals, and portfolio consolidation patterns across biotech and pharma.

Browse signals →

Strategy

Portfolio prioritization, capital allocation, and strategic repositioning across the pharmaceutical landscape.

Browse signals →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

Humanexa Platform

Go deeper with live pharmaceutical intelligence

Humanexa Signals is powered by the Humanexa intelligence engine. Track companies, assets, and competitive dynamics in real time with full dashboard access.

Explore Catalyst TrackerView full intelligence report